These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20613672)

  • 1. Isoflavones versus hormone therapy for reduction of vertebral fracture risk: indirect comparison.
    Bolaños R; Francia J
    Menopause; 2010; 17(6):1201-5. PubMed ID: 20613672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soy extracts versus hormone therapy for reduction of menopausal hot flushes: indirect comparison.
    Bolaños-Díaz R; Zavala-Gonzales JC; Mezones-Holguín E; Francia-Romero J
    Menopause; 2011 Jul; 18(7):825-9. PubMed ID: 21358349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of vertebral osteoporosis.
    Lippuner K
    Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
    Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
    J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis.
    Lindsay R; Pack S; Li Z
    Osteoporos Int; 2005 Mar; 16(3):306-12. PubMed ID: 15455193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years.
    Castelo-Branco C; Davila J; Perelló MF; Peguero A; Ros C; Martínez-Serrano MJ; Balasch J
    Climacteric; 2014 Aug; 17(4):336-41. PubMed ID: 24313640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
    Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
    Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.
    Black DM; Thompson DE
    Int J Clin Pract Suppl; 1999 Apr; 101():46-50. PubMed ID: 12669740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Compression vertebral fracture in osteoporosis--prevention and treatment].
    Vlak T
    Reumatizam; 2004; 51(2):50-3. PubMed ID: 15554379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
    Kanis JA; Barton IP; Johnell O
    Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
    J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.